Drug
Esketamine (Intranasal Spray)
Esketamine (Intranasal Spray) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
recruiting
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
NCT07146503
completedphase_1
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
NCT06795659
completedphase_3
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
NCT02497287
Clinical Trials (3)
Showing 3 of 3 trials
NCT07146503
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
NCT06795659Phase 1
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
NCT02497287Phase 3
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3